146 related articles for article (PubMed ID: 33788764)
21. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Yamamura J; Masuda N; Yamamoto D; Tsuyuki S; Yamaguchi M; Tanaka S; Tsurutani J; Tokunaga S; Yoshidome K; Mizutani M; Aono T; Ooe A; Tanino H; Matsunami N; Yasojima H; Nakayama T; Nishida Y
Chemotherapy; 2017; 62(5):307-313. PubMed ID: 28605730
[TBL] [Abstract][Full Text] [Related]
25. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer.
Sanal SM; Gokmen E; Karabulut B; Sezgin C
Breast J; 2002; 8(3):171-6. PubMed ID: 12047474
[TBL] [Abstract][Full Text] [Related]
27. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
Kim JY; Park S; Im SA; Kim SB; Sohn J; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH; Park YH;
Cancer Commun (Lond); 2019 May; 39(1):29. PubMed ID: 31138332
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Loesch D; Asmar L; McIntyre K; Doane L; Monticelli M; Paul D; Vukelja S; Orlando M; Vaughn LG; Zhan F; Boehm KA; O'Shaughnessy JA
Clin Breast Cancer; 2008 Apr; 8(2):178-86. PubMed ID: 18621615
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Yam C; Murthy RK; Valero V; Szklaruk J; Shroff GS; Stalzer CJ; Buzdar AU; Murray JL; Yang W; Hortobagyi GN; Moulder SL; Arun B
Invest New Drugs; 2018 Apr; 36(2):299-306. PubMed ID: 29374384
[TBL] [Abstract][Full Text] [Related]
30. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study.
Stemmler HJ; Kahlert S; Brudler O; Beha M; Müller S; Stauch B; Heinemann V
Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):630-5. PubMed ID: 16372489
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
Fuentes H; Calderillo G; Alexander F; Ramirez M; Avila E; Perez L; Aguirre G; Oñate-Ocaña LF; Gallardo D; Otero J
Anticancer Drugs; 2006 Jun; 17(5):565-70. PubMed ID: 16702814
[TBL] [Abstract][Full Text] [Related]
32. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Vernieri C; Prisciandaro M; Milano M; Cona MS; Maggi C; Brambilla M; Mennitto A; Fabbroni C; Farè E; Cresta S; Celio L; Mariani G; Bianchi G; Capri G; de Braud F
Clin Breast Cancer; 2019 Apr; 19(2):e306-e318. PubMed ID: 30635175
[TBL] [Abstract][Full Text] [Related]
33. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
O'Shaughnessy JA; Vukelja S; Marsland T; Kimmel G; Ratnam S; Pippen JE
Clin Breast Cancer; 2004 Jun; 5(2):142-7. PubMed ID: 15245619
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Zhou NN; Teng XY; Jiang WQ; Liu DG
Ai Zheng; 2007 Dec; 26(12):1373-6. PubMed ID: 18076805
[TBL] [Abstract][Full Text] [Related]
36. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M
J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374
[TBL] [Abstract][Full Text] [Related]
39. First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Allouache D; Gawande SR; Tubiana-Hulin M; Tubiana-Mathieu N; Piperno-Neumann S; Mefti F; Bozec L; Genot JY
BMC Cancer; 2005 Nov; 5():151. PubMed ID: 16316459
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine for palliative treatment in metastatic breast cancer.
Lüftner D; Flath B; Akrivakis C; Grunewald R; Mergenthaler HG; Possinger K
J Cancer Res Clin Oncol; 1998; 124(10):527-31. PubMed ID: 9829855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
